Dexamethasone distribution characteristic following controllable continuous sub-tenon drug delivery in rabbit

References

• Abadia B, Calvo P, Ferreras A, et al. (2016). Clinical applications of dexamethasone for aged eyes. Drugs Aging 33:639–46
   PubMed Web of Science ®Google Scholar
• Abdul NN, Agarwal P, Agarwal R, et al. (2016). Intraocular distribution of topically applied hydrophilic and lipophilic substances in rat eyes. Drug Deliv 23:2765–71
   PubMed Web of Science ®Google Scholar
• Ali J, Fazil M, Qumbar M, et al. (2016). Colloidal drug delivery system: amplify the ocular delivery. Drug Deliv 23:710–26
   PubMed Web of Science ®Google Scholar
• Battaglia L, Serpe L, Foglietta F, et al. (2016). Application of lipid nanoparticles to ocular drug delivery. Expert Opin Drug Deliv 13:1743–57
   PubMed Web of Science ®Google Scholar
• Bondalapati S, Cabrera MT. (2014). Sub-tenon triamcinolone acetonide injections for topical medication intolerance in chronic blepharokeratoconjunctivitis. Cornea 33:999–1001
   PubMed Web of Science ®Google Scholar
• Booth BA, Vidal DL, Bouhanik S, et al. (2007). Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications. Drugs Aging 24:581–602
   PubMed Web of Science ®Google Scholar
• Boye SL, Bennett A, Scalabrino ML, et al. (2016). Impact of heparan sulfate binding on transduction of retina by recombinant adeno-associated virus vectors. J Virol 90:4215–31
   PubMed Web of Science ®Google Scholar
• Coursey TG, Henriksson JT, Marcano DC, et al. (2015). Dexamethasone nanowafer as an effective therapy for dry eye disease. J Control Release 213:168–74
   PubMed Web of Science ®Google Scholar
• Dalkara D, Kolstad KD, Caporale N, et al. (2009). Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther 17:2096–102
   PubMed Web of Science ®Google Scholar
• Del AE, Urtti A. (2008). Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 13:135–43
   PubMed Web of Science ®Google Scholar
• Geroski DH, Edelhauser HF. (2001). Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 52:37–48
   PubMed Web of Science ®Google Scholar
• Ghate D, Brooks W, McCarey BE, Edelhauser HF. (2007). Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci 48:2230–7
   PubMed Web of Science ®Google Scholar
• Hsu J. (2007). Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol 18:235–9
   PubMed Web of Science ®Google Scholar
• Huang X, Liu S, Yang Y, et al. (2017). Controllable continuous sub-tenon drug delivery of dexamethasone disodium phosphate to ocular posterior segment in rabbit. Drug Deliv 24:452–8
   PubMed Web of Science ®Google Scholar
• Huang Z, Yang W, Zong Y, et al. (2016). A study of the dexamethasone sodium phosphate release properties from a periocular capsular drug delivery system. Drug Deliv 23:849–57
   PubMed Web of Science ®Google Scholar
• Hunter RS, Lobo AM. (2011). Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol 5:1613–21
   PubMedGoogle Scholar
• Jager RD, Aiello LP, Patel SC, Cunningham EJ. (2004). Risks of intravitreous injection: a comprehensive review. Retina (Philadelphia, Pa.) 24:676–98
   PubMed Web of Science ®Google Scholar
• Kim SJ, Chomsky AS, Sternberg PJ. (2013). Reducing the risk of endophthalmitis after intravitreous injection. JAMA Ophthalmol 131:674–5
   PubMed Web of Science ®Google Scholar
• Kompella UB, Kadam RS, Lee VH. (2010). Recent advances in ophthalmic drug delivery. Ther Deliv 1:435–56
   PubMedGoogle Scholar
• Maurice DM. (2002). Drug delivery to the posterior segment from drops. Surv Ophthalmol 47:S41–52
   PubMed Web of Science ®Google Scholar
• Nan K, Sun S, Li Y, et al. (2010). Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection. Br J Ophthalmol 94:654–8
   PubMed Web of Science ®Google Scholar
• Pescina S, Santi P, Ferrari G, et al. (2012). Ex vivo models to evaluate the role of ocular melanin in trans-scleral drug delivery. Eur J Pharm Sci 46:475–83
   PubMed Web of Science ®Google Scholar
• Pohlmann D, Winterhalter S, Pleyer U. (2016). Intravitreal dexamethasone for the treatment of CMO associated with refractory sclerouveitis. Ocul Immunol Inflamm. [Epub ahead of print]. doi: 10.1080/09273948.2016.1196712
   PubMed Web of Science ®Google Scholar
• Pokharkar V, Patil V, Mandpe L. (2015). Engineering of polymer-surfactant nanoparticles of doxycycline hydrochloride for ocular drug delivery. Drug Deliv 22:955–68
   PubMed Web of Science ®Google Scholar
• Raghava S, Hammond M, Kompella UB. (2004). Periocular routes for retinal drug delivery. Expert Opin Drug Deliv 1:99–114
   PubMed Web of Science ®Google Scholar
• Ranta VP, Mannermaa E, Lummepuro K, et al. (2010). Barrier analysis of periocular drug delivery to the posterior segment. J Control Release 148:42–8
   PubMed Web of Science ®Google Scholar
• Shah CP, Garg SJ, Vander JF, et al. (2011). Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology 118:2028–34
   PubMed Web of Science ®Google Scholar
• Sun S, Li J, Li X, et al. (2016). Episcleral drug film for better-targeted ocular drug delivery and controlled release using multilayered poly-epsilon-caprolactone (PCL). Acta Biomater 37:143–54
   PubMed Web of Science ®Google Scholar
• Thakur A, Kadam RS, Kompella UB. (2011). Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids. Drug Metab Dispos 39:771–81
   PubMed Web of Science ®Google Scholar
• Thakur SR, Tekko I, McAvoy K, et al. (2017). Minimally invasive microneedles for ocular drug delivery. Expert Opin Drug Deliv 14:525–37
   PubMed Web of Science ®Google Scholar
• Thrimawithana TR, Young S, Bunt CR, et al. (2011). Drug delivery to the posterior segment of the eye. Drug Discov Today 16:270–7
   PubMed Web of Science ®Google Scholar
• Weijtens O, Feron EJ, Schoemaker RC, et al. (1999). High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol 128:192–7
   PubMed Web of Science ®Google Scholar
• Whitcup SM, Robinson MR. (2015). Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis. Ann N Y Acad Sci 1358:1–12
   PubMed Web of Science ®Google Scholar
• Yavuz B, Bozdag PS, Kaffashi A, et al. (2016). In vivo tissue distribution and efficacy studies for cyclosporin A loaded nano-decorated subconjunctival implants. Drug Deliv 23:3279–84
   PubMed Web of Science ®Google Scholar
• Yellepeddi VK, Palakurthi S. (2016). Recent advances in topical ocular drug delivery. J Ocul Pharmacol Ther 32:67–82
   PubMed Web of Science ®Google Scholar
• Zeng A, Dong K, Wang M, et al. (2016). Investigation of the colon-targeting, improvement on the side-effects and therapy on the experimental colitis in mouse of a resin microcapsule loading dexamethasone sodium phosphate. Drug Deliv 23:1992–2002
   PubMed Web of Science ®Google Scholar